Appili Therapeutics Inc. (Appili), an anti-infective drug development company, announced today that Sean McBride, a 26-year pharmaceutical veteran, has joined the company as vice president of business development.
Mr. McBride will lead Appili’s out-licensing, product in-licensing and acquisition opportunities as the company builds its pipeline of infectious disease products.
“We are delighted to have Mr. McBride join our strong leadership team,” said Kevin Sullivan, CEO of Appili Therapeutics. “Sean’s experience in international deal-making, along with his expertise in pharmaceutical sales and marketing will be invaluable as we build our balanced-risk pipeline of near-to-revenue opportunities with higher-risk, transformational drugs that can truly change the way we treat infectious disease.”
“This is an exciting time to be joining the Appili team as it seeks to take advantage of the many incentives aimed at fighting antibiotic resistance and grow its pipeline of anti-infectives,” said Mr. McBride. “There are many players, including government, non-profit, and for-profit organizations, with an interest in infectious diseases and I look forward to bringing my experience working with these organizations, and contributing to the company’s future success.”
Mr. McBride brings more than two decades of experience within the Canadian pharmaceutical and biotechnology industry. His expertise lies in licensing, purchasing and divesting assets, in addition to advancing the commercialization of early stage assets and identifying opportunities for growth.
Prior to joining Appili, Mr. McBride spent 10 years at GlaxoSmithKline Inc. (GSK) serving in many roles of increasing responsibility. Most recently he served as head of an entrepreneurial business unit where he negotiated global asset transactions and was responsible for the commercial success of over 40 brand assets. Prior to joining GSK, Mr. McBride served as a director for healthcare agencies conducting commercial and strategic assessments in both Canada and the US and also served as director of marketing with Roche Pharmaceuticals. Mr. McBride has a bachelor of business administration from Simon Fraser University.
About Appili Therapeutics Inc.
Appili is dedicated to identifying, acquiring and advancing novel therapeutics for infectious disease. The company has two anti-infective programs, ATI-1501 and ATI-1503, in its pipeline. ATI-1501 is a taste-masked treatment for anaerobic infections that has been granted orphan drug status by the FDA. Appili plans to take ATI-1501 into clinical trials in 2017. Appili’s second product, ATI-1503, is a novel antibiotic with broad potential to treat deadly Gram-negative infections. These drug-resistant infections have been identified by the U.S. Centers for Disease Control (CDC) and the World Health Organization as posing the highest threat to human health. For more information visit www.AppiliTherapeutics.com.
For more information, please contact:
July 6, 2017, Halifax, Nova Scotia